The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials

The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials

Objective: The meta-analysis was used to evaluate the skeletal-related events (SREs) and efficacy of denosumab versus zoledronic acid (ZA) in patients with bone metastases. Methods: The data of this meta-analysis study were searched from PUBMED, EMBASE, Cochrane Library, Web of Science with Conferen...

Full description

Bibliographic Details
Main Authors:	Zhicai Zhang, Feifei Pu, Zengwu Shao
Format:	Article
Language:	English
Published:	Elsevier 2017-11-01
Series:	Journal of Bone Oncology
Online Access:	http://www.sciencedirect.com/science/article/pii/S2212137416300859

Similar Items

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial
by: Jiaji Yue, et al.
Published: (2022-08-01)

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial
by: Shenglong Li, et al.
Published: (2019-04-01)

Denosumab versus zoledronic acid in elderly patients after hip fracture
by: Seung-Ju Kim, et al.
Published: (2022-12-01)

Sequential therapy with denosumab and zoledronate for osteoporosis management a randomized controlled trial
by: Hung-Kuan Yen, et al.
Published: (2023-12-01)

Efficacy and safety of denosumab versus zoledronic acid in delaying skeletal-related events in patients with gastrointestinal cancer, pancreas-biliary system cancer, and other rare cancers
by: Hiroo Imai, et al.
Published: (2017-03-01)

Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
by: Stopeck AT, et al.
Published: (2012-04-01)

A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial
by: Chia-Che Lee, et al.
Published: (2021-09-01)

Comparison of Denosumab and Zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of bone
by: Himanshu Kanwat, et al.
Published: (2021-07-01)

Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials
by: Lianghai Jiang, et al.
Published: (2021-06-01)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
by: Si Su, et al.
Published: (2023-11-01)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
by: Ruxu You, et al.
Published: (2022-03-01)

Clinical efficacy of customized modular prosthesis in the treatment of femoral shaft metastases
by: Feifei Pu, et al.
Published: (2023-04-01)

Comparison of the Efficacy of Zoledronate and Denosumab in Patients with Acute Osteoporotic Vertebral Compression Fractures: A Randomized Controlled Trial
by: Seong Son, et al.
Published: (2024-04-01)

Pharmacoeconomic analysis of denosumab in patients with breast cancer and bone metastases
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion
by: Guenther G. Steger, et al.
Published: (2011-09-01)

Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years
by: Chi Zhang, et al.
Published: (2018-11-01)

Giant cell tumour of bone in os sacrum of a prepubertal girl – Surgical and medical treatment with zoledronate and denosumab
by: Signe Sparre Beck-Nielsen, et al.
Published: (2023-06-01)

Management of bone metastases in refractory prostate cancer – role of denosumab
by: Paller CJ, et al.
Published: (2012-09-01)

Cost-Effectiveness Analysis of Denosumab in the Prevention of Skeletal-Related Events Among Patients With Breast Cancer With Bone Metastasis in India
by: Raina Wadhwa, et al.
Published: (2024-03-01)

Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach
by: Dionna Jacobson, et al.
Published: (2022-06-01)

A Retrospective Analysis of Denosumab for the Treatment of Bone Metastases in Chinese Patients With Breast Cancer
by: Wei Li, et al.
Published: (2023-07-01)

Denosumab for Breast Cancer with Bone Metastases-Induced Hypercalcemia Complicated with Acute Renal Failure
by: Chen-Yu Kuo, et al.
Published: (2015-06-01)

Treatment of medullary thyroid cancer with bone metastases with denosumab: A review and case illustration
by: Leslie S. Eldeiry, et al.
Published: (2020-09-01)

Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases
by: Thomas J Polascik
Published: (2008-12-01)

Denosumab and Zoledronic Acid Differently Affect Circulating Immune Subsets: A Possible Role in the Onset of MRONJ
by: Ilaria Roato, et al.
Published: (2023-10-01)

Potential protective effect of zoledronic acid when switching from long-term therapy of osteoporosis with denosumab
by: O. V. Yakushevskaya
Published: (2021-01-01)

Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw
by: Pei-An Fu, et al.
Published: (2023-05-01)

Economic evaluation of denosumab in the prevention of skeletal-related events in patients with multiple myeloma in Mexico
by: Fernando Carlos-Rivera, et al.
Published: (2022-04-01)

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval
by: Benoit Cadieux, et al.
Published: (2022-04-01)

Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
by: Soraia Lobo-Martins, et al.
Published: (2020-07-01)

Denosumab administration for bone metastases from solid tumors: a retrospective cross-sectional study
by: Kohei Mizuta, et al.
Published: (2023-10-01)

Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid
by: Matti Aapro, et al.
Published: (2012-04-01)

Editorial: Diagnosis and treatment of bone metastases
by: Feifei Pu, et al.
Published: (2023-08-01)

The Effectiveness of Zoledronic Acid and Ibandronic Acid in Delaying Skeletal-Related Events in Multiple Myeloma in Indonesia
by: Nutrisia Aquariushinta Sayuti, et al.
Published: (2020-09-01)

Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
by: Jolan Dupont, et al.
Published: (2022-06-01)

ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS
by: S Yu Vorotnikova, et al.
Published: (2016-12-01)

OUR EXPERIENCE WITH ZOLEDRONIC ACID IN THE TREATMENT OF PATIENTS WITH NON- SMALL CELL LUNG CANCER AND BONE METASTASES
by: Deyan N. Davidov
Published: (2013-04-01)

Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events.
by: Salvatore Grisanti, et al.
Published: (2019-01-01)

Cardiovascular Safety in Postmenopausal Women and Men With Osteoporosis Treated With Denosumab and Zoledronic Acid: A Post‐Authorization Safety Study
by: Leslie Spangler, et al.
Published: (2023-10-01)

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
by: Vittorio Fusco, et al.
Published: (2018-09-01)